Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
<p><strong>Background</strong></p> To understand the kinetics of immune responses with different dosing gaps of the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two different dosing gaps. <p><strong>Methods</strong></p&g...
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
Wiley
2022
|
| _version_ | 1826310957839679488 |
|---|---|
| author | Jeewandara, C Aberathna, IS Gomes, L Pushpakumara, PD Danasekara, S Guruge, D Ranasinghe, T Gunasekera, B Kamaladasa, A Kuruppu, H Somathilake, G Dissanayake, O Gamalath, N Ekanayake, D Jayamali, J Jayathilaka, D Mudunkotuwa, A Harvie, M Nimasha, T Wijayamuni, R Schimanski, L Rijal, P Tan, TK Dong, T Townsend, A Ogg, GS Malavige, GN |
| author_facet | Jeewandara, C Aberathna, IS Gomes, L Pushpakumara, PD Danasekara, S Guruge, D Ranasinghe, T Gunasekera, B Kamaladasa, A Kuruppu, H Somathilake, G Dissanayake, O Gamalath, N Ekanayake, D Jayamali, J Jayathilaka, D Mudunkotuwa, A Harvie, M Nimasha, T Wijayamuni, R Schimanski, L Rijal, P Tan, TK Dong, T Townsend, A Ogg, GS Malavige, GN |
| author_sort | Jeewandara, C |
| collection | OXFORD |
| description | <p><strong>Background</strong></p>
To understand the kinetics of immune responses with different dosing gaps of the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two different dosing gaps.
<p><strong>Methods</strong></p>
Antibodies to the SARS-CoV-2 virus were assessed in 297 individuals with a dosing gap of 12 weeks, sampled 12 weeks post second dose (cohort 1) and in 77 individuals with a median dosing gap of 21.4 weeks (cohort 2) sampled 6 weeks post second dose. ACE2-blocking antibodies (ACE2-blocking Abs), antibodies to the receptor-binding domain (RBD) of variants of concern (VOC), and ex vivo T cell responses were assessed in a subcohort.
<p><strong>Results</strong></p>
All individuals (100%) had SARS-CoV-2-specific total antibodies and 94.2% of cohort 1 and 97.1% of cohort 2 had ACE2-blocking Abs. There was no difference in antibody titers or positivity rates in different age groups in both cohorts. The ACE2-blocking Abs (p < .0001) and antibodies to the RBD of the VOCs were significantly higher in cohort 2 compared to cohort 1. 41.2% to 65.8% of different age groups gave a positive response by the hemagglutination assay to the RBD of the ancestral virus and VOCs in cohort 1, while 53.6%–90% gave a positive response in cohort 2. 17/57 (29.8%) of cohort 1 and 17/29 (58.6%) of cohort 2 had ex vivo interferon (IFN)γ ELISpot responses above the positive threshold. The ACE2-blocking antibodies (Spearman's r = .46, p = .008) and ex vivo IFNγ responses (Spearman's r = .71, p < .0001) at 12 weeks post first dose, significantly correlated with levels 12 weeks post second dose.
<p><strong>Conclusions</strong></p>
Both dosing schedules resulted in high antibody and T cell responses post vaccination, although those with a longer dosing gap had a higher magnitude of responses, possibly as immune responses were measured 6 weeks post second dose compared to 12 weeks post second dose. |
| first_indexed | 2024-03-07T08:01:15Z |
| format | Journal article |
| id | oxford-uuid:e7f6a631-7ec1-47f3-a7a0-4e3aac6e5ce4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:01:15Z |
| publishDate | 2022 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:e7f6a631-7ec1-47f3-a7a0-4e3aac6e5ce42023-09-26T14:58:24ZKinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individualsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e7f6a631-7ec1-47f3-a7a0-4e3aac6e5ce4EnglishSymplectic ElementsWiley2022Jeewandara, CAberathna, ISGomes, LPushpakumara, PDDanasekara, SGuruge, DRanasinghe, TGunasekera, BKamaladasa, AKuruppu, HSomathilake, GDissanayake, OGamalath, NEkanayake, DJayamali, JJayathilaka, DMudunkotuwa, AHarvie, MNimasha, TWijayamuni, RSchimanski, LRijal, PTan, TKDong, TTownsend, AOgg, GSMalavige, GN<p><strong>Background</strong></p> To understand the kinetics of immune responses with different dosing gaps of the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two different dosing gaps. <p><strong>Methods</strong></p> Antibodies to the SARS-CoV-2 virus were assessed in 297 individuals with a dosing gap of 12 weeks, sampled 12 weeks post second dose (cohort 1) and in 77 individuals with a median dosing gap of 21.4 weeks (cohort 2) sampled 6 weeks post second dose. ACE2-blocking antibodies (ACE2-blocking Abs), antibodies to the receptor-binding domain (RBD) of variants of concern (VOC), and ex vivo T cell responses were assessed in a subcohort. <p><strong>Results</strong></p> All individuals (100%) had SARS-CoV-2-specific total antibodies and 94.2% of cohort 1 and 97.1% of cohort 2 had ACE2-blocking Abs. There was no difference in antibody titers or positivity rates in different age groups in both cohorts. The ACE2-blocking Abs (p < .0001) and antibodies to the RBD of the VOCs were significantly higher in cohort 2 compared to cohort 1. 41.2% to 65.8% of different age groups gave a positive response by the hemagglutination assay to the RBD of the ancestral virus and VOCs in cohort 1, while 53.6%–90% gave a positive response in cohort 2. 17/57 (29.8%) of cohort 1 and 17/29 (58.6%) of cohort 2 had ex vivo interferon (IFN)γ ELISpot responses above the positive threshold. The ACE2-blocking antibodies (Spearman's r = .46, p = .008) and ex vivo IFNγ responses (Spearman's r = .71, p < .0001) at 12 weeks post first dose, significantly correlated with levels 12 weeks post second dose. <p><strong>Conclusions</strong></p> Both dosing schedules resulted in high antibody and T cell responses post vaccination, although those with a longer dosing gap had a higher magnitude of responses, possibly as immune responses were measured 6 weeks post second dose compared to 12 weeks post second dose. |
| spellingShingle | Jeewandara, C Aberathna, IS Gomes, L Pushpakumara, PD Danasekara, S Guruge, D Ranasinghe, T Gunasekera, B Kamaladasa, A Kuruppu, H Somathilake, G Dissanayake, O Gamalath, N Ekanayake, D Jayamali, J Jayathilaka, D Mudunkotuwa, A Harvie, M Nimasha, T Wijayamuni, R Schimanski, L Rijal, P Tan, TK Dong, T Townsend, A Ogg, GS Malavige, GN Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals |
| title | Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals |
| title_full | Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals |
| title_fullStr | Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals |
| title_full_unstemmed | Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals |
| title_short | Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals |
| title_sort | kinetics of immune responses to the azd1222 covishield vaccine with varying dose intervals in sri lankan individuals |
| work_keys_str_mv | AT jeewandarac kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT aberathnais kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT gomesl kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT pushpakumarapd kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT danasekaras kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT guruged kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT ranasinghet kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT gunasekerab kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT kamaladasaa kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT kuruppuh kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT somathilakeg kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT dissanayakeo kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT gamalathn kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT ekanayaked kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT jayamalij kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT jayathilakad kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT mudunkotuwaa kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT harviem kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT nimashat kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT wijayamunir kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT schimanskil kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT rijalp kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT tantk kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT dongt kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT townsenda kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT ogggs kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals AT malavigegn kineticsofimmuneresponsestotheazd1222covishieldvaccinewithvaryingdoseintervalsinsrilankanindividuals |